[Skip to content]

EPDA - European Parkinsons Disease Association

EPDA - European Parkinsons Disease Association

EPDA - Awareness

EPDA - Coping Strategies

EPDA - Medical Information

EPDA - Patient Guide

EPDA - Site Map

EPDA - Rewrite Tomorrow

Contact Us |
Login |
Accessibility |
Low graphics |
Text Size: A A A

EUROPEAN PARKINSON'S DISEASE ASSOCIATION

.

International news and press releases

Recent news

Cohesion policy for all - Commissioner Hahn commits with the UN Convention on the rights of persons with disabilitiesIt is crucial that EU money is invested on improving the lives of all European citizens, including people with disabilities. EDF wants to make sure that accessibility, non-discrimination and social inclusion, as well as the implementation of the UN Convention on the Rights of Persons with Disabilities (UNCRPD) are key goals of the EU Structural Funds. Yesterday EDF President, Yannis Vardakastanis, met the Commissioner for Regional Policy, Johannes Hahn, in order to discuss the future Cohesion Policy 2014-20 16 May 2012
Newron Reports Completion of Phase III program for Safinamide in early and advanced Parkinson's disease patientsNewron Pharmaceuticals S.p.A. (Newron), a research and development company focused on novel CNS and pain therapies announces the top line results from the last two phase III studies of safinamide as an add-on treatment in both early (MOTION1) and advanced (SETTLE2) Parkinson's disease (PD) atients. 14 May 2012
Newron and Zambon enter into a strategic collaboration and licence agreement for SafinamideNewron Pharmaceuticals S.p.A. (Newron), a research and development company focused on novel CNS and pain therapies announces that it has executed with Zambon, the Italian chemical and pharmaceutical Company (Zambon), a strategic collaboration and licence agreement for Newron's lead compound safinamide. 14 May 2012
Low serum uric acid concentration in Parkinson's disease in southern SpainThis study produced consistent findings that UA might have a protective effect against Parkinson's disease and could influence its clinical progression. 12 May 2012
Vitamin K2: new hope for Parkinson's patientsNeuroscientist Patrik Verstreken, associated with VIB and KU Leuven, succeeded in undoing the effect of one of the genetic defects that leads to Parkinson's using vitamin K2. His discovery gives hope to Parkinson's patients. This research was done in collaboration with colleagues from Northern Illinois University (US) and will be published this evening on the website of the authorative journal Science. 10 May 2012
Structural funds: The European Parliament sends a strong message on disability to the member statesDuring a workshop organised on 8 May by EDF and MEP Danuta Hübner (EPP, Poland), the European Parliament sent a strong messages to the Members States: the removal of crucial conditionalities is not acceptable: the future Cohesion Policy 2014-2020 will have to include persons with disabilities. 09 May 2012
Sustained translational repression by eIF2α-P mediates prion neurodegenerationGiven the prevalence of protein misfolding and activation of the unfolded protein response in several neurodegenerative diseases, these results suggest that manipulation of common pathways such as translational control, rather than disease-specific approaches, may lead to new therapies preventing synaptic failure and neuronal loss across the spectrum of these disorders. 06 May 2012
Canada and Israel join JPNDCanada has joined JPND as the first ever Third Country member. Israel joins as full member to bring total number of countries participating in JPND to 27. 04 May 2012
How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorderPatients with idiopathic REM sleep behaviour disorder in an ongoing cohort study were evaluated annually with several quantitative motor measures, including the Unified Parkinson's Disease Rating Scale, Purdue Pegboard, alternate-tap test and timed up-and-go. Patients who developed parkinsonism were identified from this cohort and matched according to age to normal controls. 04 May 2012
Viral-toxin interactions and Parkinson's disease: poly(I:C) priming enhanced the neurodegenerative effects of paraquatThese findings suggest that viral agents can sensitize microglial-dependent inflammatory responses, thereby rendering nigral DA neurons vulnerable to further environmental toxin exposure. 04 May 2012
HEIDI : A new way of sharing and storing health information in the EUHEIDI an internet based wiki that presents reliable and comparable data about health in the EU has been launched by the European Commission's Directorate-General for Health & Consumers. Although Heidi has been set up by the Commission, the content is written by European health experts who are responsible for their contributions and can directly upload and edit information. 03 May 2012
Role for α6 nicotinic receptors in L-dopa-induced dyskinesias in parkinsonian miceTo conclude, the similar declines in L-dopa-induced AIMs in nicotine-treated wildtype mice and in α6(-/-) mice treated with and without nicotine indicate an essential role for α6β2* nAChRs in the maintenance of L-dopa-induced AIMs. These findings suggest that α6β2* nAChR drugs have potential for reducing L-dopa-induced dyskinesias in Parkinson's disease. 03 May 2012
Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's diseaseNo significant differences were found in UPDRS scores for subjects taking antidepressants compared with those not taking antidepressants. Tricyclic antidepressants are associated with a delay in reaching the end point of need to start dopaminergic therapy. The lack of change in overall UPDRS scores suggests the delay was not attributable to symptomatic effects. 03 May 2012
Physiological Phenotype and Vulnerability in Parkinson's DiseaseBecause much of the mitochondrial burden created by this at-risk phenotype is created by Ca2+ entry through L-type voltage-dependent channels for which there are antagonists approved for human use, a neuroprotective strategy to reduce this burden is feasible. 02 May 2012
Successful Outcome for V81444 in Phase I StudyVernalis plc today announces the successful outcome of its Phase I trial of V81444, its adenosine A2A antagonist with potential application in Parkinson's Disease and other CNS indications. The double-blind, placebo controlled study investigated single and multiple ascending doses and was conducted in healthy male volunteers. 02 May 2012
New post-hoc analyses examined Neupro effects on pain, depressed mood, apathy and fatigue in patients with Parkinson's diseaseBrussels (Belgium), APRIL 26th 2012, 1800 CET Insights into the effects of Neupro (rotigotine transdermal system) on common non-motor symptoms of Parkinson's disease (PD) were presented today at the 64th AAN Annual Meeting in New Orleans, USA. 02 May 2012
Is alpha-synuclein in the colon a biomarker for premotor Parkinson's Disease? Evidence from 3 casesAll subjects showed immunostaining for alpha-synuclein (two, five and two years before first motor Parkinson's disease symptom). No similar alpha-synuclein immunostaining was seen in 23 healthy controls. Staining of samples for substance P suggested colocalization of alpha-synuclein and substance P in perikarya and neurites. 01 May 2012
Considerations Regarding the Etiology and Future Treatment of Autosomal Recessive Versus Idiopathic Parkinson DiseaseThe authors briefly draw attention to aspects of existing pharmacological and surgical therapies as they relate to the PARK2-linked variant; thereafter, they comment on new research avenues that are aimed at future therapeutic interventions to eventually slow or arrest the progression of a first variant of PD. 01 May 2012
Short and valid assessment of apraxia in Parkinson's diseaseNo association was found between the AST and MDS-UPDRS part III, indicating that AST discriminates well (discriminative validity) between apraxia and parkinsonism. Furthermore, AST was associated with ADL and Hoehn & Yahr stage (convergent validity). 01 May 2012
Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulationSome non-motor symptoms improve after DBS, partly because of motor benefit or reduction of drug treatment, and partly as a direct effect of stimulation. More evidence on the effects of DBS on non-motor symptoms is needed and specifically designed studies are warranted. 01 May 2012

Page: [1] [2] [3] [4] [5] [6]

[ Next » ]

Medical and pharmaceutical news

Newron Reports Completion of Phase III program for Safinamide in early and advanced Parkinson's disease patientsNewron Pharmaceuticals S.p.A. (Newron), a research and development company focused on novel CNS and pain therapies announces the top line results from the last two phase III studies of safinamide as an add-on treatment in both early (MOTION1) and advanced (SETTLE2) Parkinson's disease (PD) atients. 14 May 2012
Newron and Zambon enter into a strategic collaboration and licence agreement for SafinamideNewron Pharmaceuticals S.p.A. (Newron), a research and development company focused on novel CNS and pain therapies announces that it has executed with Zambon, the Italian chemical and pharmaceutical Company (Zambon), a strategic collaboration and licence agreement for Newron's lead compound safinamide. 14 May 2012
Vitamin K2: new hope for Parkinson's patientsNeuroscientist Patrik Verstreken, associated with VIB and KU Leuven, succeeded in undoing the effect of one of the genetic defects that leads to Parkinson's using vitamin K2. His discovery gives hope to Parkinson's patients. This research was done in collaboration with colleagues from Northern Illinois University (US) and will be published this evening on the website of the authorative journal Science. 10 May 2012
Successful Outcome for V81444 in Phase I StudyVernalis plc today announces the successful outcome of its Phase I trial of V81444, its adenosine A2A antagonist with potential application in Parkinson's Disease and other CNS indications. The double-blind, placebo controlled study investigated single and multiple ascending doses and was conducted in healthy male volunteers. 02 May 2012
New post-hoc analyses examined Neupro effects on pain, depressed mood, apathy and fatigue in patients with Parkinson's diseaseBrussels (Belgium), APRIL 26th 2012, 1800 CET Insights into the effects of Neupro (rotigotine transdermal system) on common non-motor symptoms of Parkinson's disease (PD) were presented today at the 64th AAN Annual Meeting in New Orleans, USA. 02 May 2012
Weighing Different Scales: Unified Dyskinesia Rating Scale Comes out on Top, Could Speed Development of New Dyskinesia TreatmentResearchers funded by The Michael J. Fox Foundation (MJFF) have identified the best clinical scale for measuring patient response to therapies to treat dyskinesia, the debilitating, uncontrollable movements that are often a side effect of Parkinson's disease (PD) drugs. 01 May 2012
MHRA seizes more than £25 million of counterfeit medicine in last five years as new anti-counterfeiting strategy launchesAs the Medicines and Healthcare products Regulatory Agency (MHRA) launches its second anti-counterfeiting strategy, the UK medicines regulator reveals it has seized more than £25 million of counterfeit and stolen medicines in the last five years. 01 May 2012
Rainbow Biosciences, LLC Enters into Letter of Intent with Amarantus BioSciences to Advance Parkinson's Disease ProgramRainbow BioSciences, a subsidiary of Rainbow Coral Corp has executed a Letter Of Intent to advance Amarantus BioSciences, Inc.'s Parkinson's disease program, comprised of an early detection diagnostic blood test and a diseasemodifying protein drug candidate. 30 April 2012
Sanofi and Michael J. Fox Foundation Collaborate on Potential New Treatment for Parkinson's DiseaseParis, France - April 19, 2012 - Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it has entered into a collaboration with the Michael J. Fox Foundation (MJFF) to conduct a clinical trial to assess the safety and tolerability of AVE 8112, a Sanofi PDE4 inhibitor phosphodiesterase type 4 inhibitor - in patients with Parkinson's disease (PD). 20 April 2012
Unmet needs in Parkinson's disease - survey report publishedThis report presents the findings of a survey conducted at the European Federation of Neurological Societies (EFNS) Congress in Budapest, 1013 September 2011. The survey aimed to identify the unmet needs in the treatment of patients with Parkinson's disease, as perceived by clinicians. 19 April 2012

Page: [1] [2]

[ Next » ]

Research News

Low serum uric acid concentration in Parkinson's disease in southern SpainThis study produced consistent findings that UA might have a protective effect against Parkinson's disease and could influence its clinical progression. 12 May 2012
Sustained translational repression by eIF2α-P mediates prion neurodegenerationGiven the prevalence of protein misfolding and activation of the unfolded protein response in several neurodegenerative diseases, these results suggest that manipulation of common pathways such as translational control, rather than disease-specific approaches, may lead to new therapies preventing synaptic failure and neuronal loss across the spectrum of these disorders. 06 May 2012
How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorderPatients with idiopathic REM sleep behaviour disorder in an ongoing cohort study were evaluated annually with several quantitative motor measures, including the Unified Parkinson's Disease Rating Scale, Purdue Pegboard, alternate-tap test and timed up-and-go. Patients who developed parkinsonism were identified from this cohort and matched according to age to normal controls. 04 May 2012
Viral-toxin interactions and Parkinson's disease: poly(I:C) priming enhanced the neurodegenerative effects of paraquatThese findings suggest that viral agents can sensitize microglial-dependent inflammatory responses, thereby rendering nigral DA neurons vulnerable to further environmental toxin exposure. 04 May 2012
Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's diseaseNo significant differences were found in UPDRS scores for subjects taking antidepressants compared with those not taking antidepressants. Tricyclic antidepressants are associated with a delay in reaching the end point of need to start dopaminergic therapy. The lack of change in overall UPDRS scores suggests the delay was not attributable to symptomatic effects. 03 May 2012
Role for α6 nicotinic receptors in L-dopa-induced dyskinesias in parkinsonian miceTo conclude, the similar declines in L-dopa-induced AIMs in nicotine-treated wildtype mice and in α6(-/-) mice treated with and without nicotine indicate an essential role for α6β2* nAChRs in the maintenance of L-dopa-induced AIMs. These findings suggest that α6β2* nAChR drugs have potential for reducing L-dopa-induced dyskinesias in Parkinson's disease. 03 May 2012
Physiological Phenotype and Vulnerability in Parkinson's DiseaseBecause much of the mitochondrial burden created by this at-risk phenotype is created by Ca2+ entry through L-type voltage-dependent channels for which there are antagonists approved for human use, a neuroprotective strategy to reduce this burden is feasible. 02 May 2012
Short and valid assessment of apraxia in Parkinson's diseaseNo association was found between the AST and MDS-UPDRS part III, indicating that AST discriminates well (discriminative validity) between apraxia and parkinsonism. Furthermore, AST was associated with ADL and Hoehn & Yahr stage (convergent validity). 01 May 2012
Is alpha-synuclein in the colon a biomarker for premotor Parkinson's Disease? Evidence from 3 casesAll subjects showed immunostaining for alpha-synuclein (two, five and two years before first motor Parkinson's disease symptom). No similar alpha-synuclein immunostaining was seen in 23 healthy controls. Staining of samples for substance P suggested colocalization of alpha-synuclein and substance P in perikarya and neurites. 01 May 2012
Considerations Regarding the Etiology and Future Treatment of Autosomal Recessive Versus Idiopathic Parkinson DiseaseThe authors briefly draw attention to aspects of existing pharmacological and surgical therapies as they relate to the PARK2-linked variant; thereafter, they comment on new research avenues that are aimed at future therapeutic interventions to eventually slow or arrest the progression of a first variant of PD. 01 May 2012

Page: [1] [2] [3] [4]

[ Next » ]

Political news

Cohesion policy for all - Commissioner Hahn commits with the UN Convention on the rights of persons with disabilitiesIt is crucial that EU money is invested on improving the lives of all European citizens, including people with disabilities. EDF wants to make sure that accessibility, non-discrimination and social inclusion, as well as the implementation of the UN Convention on the Rights of Persons with Disabilities (UNCRPD) are key goals of the EU Structural Funds. Yesterday EDF President, Yannis Vardakastanis, met the Commissioner for Regional Policy, Johannes Hahn, in order to discuss the future Cohesion... 16 May 2012
Structural funds: The European Parliament sends a strong message on disability to the member statesDuring a workshop organised on 8 May by EDF and MEP Danuta Hübner (EPP, Poland), the European Parliament sent a strong messages to the Members States: the removal of crucial conditionalities is not acceptable: the future Cohesion Policy 2014-2020 will have to include persons with disabilities. 09 May 2012
Canada and Israel join JPNDCanada has joined JPND as the first ever Third Country member. Israel joins as full member to bring total number of countries participating in JPND to 27. 04 May 2012
HEIDI : A new way of sharing and storing health information in the EUHEIDI an internet based wiki that presents reliable and comparable data about health in the EU has been launched by the European Commission's Directorate-General for Health & Consumers. Although Heidi has been set up by the Commission, the content is written by European health experts who are responsible for their contributions and can directly upload and edit information. 03 May 2012
Unmet needs in Parkinson's disease - survey report publishedThis report presents the findings of a survey conducted at the European Federation of Neurological Societies (EFNS) Congress in Budapest, 1013 September 2011. The survey aimed to identify the unmet needs in the treatment of patients with Parkinson's disease, as perceived by clinicians. 19 April 2012
Abbott's Investigational Treatment for Advanced Parkinson's Disease Demonstrates Positive Results in Phase 3 Clinical TrialAbbott announced today the results from a Phase 3 trial evaluating the company's investigational compound for advanced Parkinson's disease, levodopa-carbidopa intestinal gel (LCIG). The study showed that patients treated with LCIG for 12 weeks reported clinically meaningful and statistically significant improvements in "off" time compared to levodopa-carbidopa immediate release (IR) tablets, without increasing troublesome dyskinesia. 17 April 2012
EMA reflection paper with practical guidance on the assurance of ethical and GCP standards in the conduct of clinical trials....The European Medicines Agency publishes the final reflection paper on ethical and good clinical practice (GCP) aspects of clinical trials of medicinal products for human use conducted outside of the European Union (EU)/European Economic Area (EEA) and submitted in marketing authorisation applications to the EU regulatory authorities. 16 April 2012
UCB marks World Parkinson's Disease Day with new 'Parkinson's Well-Being Map'Brussels, Belgium, 11th April 2012, 0700 CET UCB is announcing a new initiative for World Parkinson's Disease Day 2012 that is designed to support communication around all aspects of Parkinson's Disease (PD). The Parkinson's Well-Being Map is a visual tool designed to help people with PD discuss their health status and well-being with their care teams. A new video 'Living with Parkinson's Disease: Insights and Inspirations' is also shared today and gives a voice to people with Parkinson's on... 11 April 2012
Better protection of public health: European Medicines Agency counts down to introduction of new pharmacovigilance legislationThe European Medicines Agency, together with the European Member States and the European Commission, is preparing for the introduction of the new pharmacovigilance legislation in July 2012. 02 February 2012
Eurobarometer survey Active AgeingAs the 2012 European Year for Active Ageing and Solidarity between Generations gets off the ground, the European Commission has published an extensive survey on active ageing to understand citizens' views and attitudes towards older people. 26 January 2012

Page: [1] [2]

[ Next » ]

Other news

Cohesion policy for all - Commissioner Hahn commits with the UN Convention on the rights of persons with disabilitiesIt is crucial that EU money is invested on improving the lives of all European citizens, including people with disabilities. EDF wants to make sure that accessibility, non-discrimination and social inclusion, as well as the implementation of the UN Convention on the Rights of Persons with Disabilities (UNCRPD) are key goals of the EU Structural Funds. Yesterday EDF President, Yannis Vardakastanis, met the Commissioner for Regional Policy, Johannes Hahn, in order to discuss the future Cohesion... 16 May 2012
Structural funds: The European Parliament sends a strong message on disability to the member statesDuring a workshop organised on 8 May by EDF and MEP Danuta Hübner (EPP, Poland), the European Parliament sent a strong messages to the Members States: the removal of crucial conditionalities is not acceptable: the future Cohesion Policy 2014-2020 will have to include persons with disabilities. 09 May 2012
Canada and Israel join JPNDCanada has joined JPND as the first ever Third Country member. Israel joins as full member to bring total number of countries participating in JPND to 27. 04 May 2012
HEIDI : A new way of sharing and storing health information in the EUHEIDI an internet based wiki that presents reliable and comparable data about health in the EU has been launched by the European Commission's Directorate-General for Health & Consumers. Although Heidi has been set up by the Commission, the content is written by European health experts who are responsible for their contributions and can directly upload and edit information. 03 May 2012
Abbott's Investigational Treatment for Advanced Parkinson's Disease Demonstrates Positive Results in Phase 3 Clinical TrialAbbott announced today the results from a Phase 3 trial evaluating the company's investigational compound for advanced Parkinson's disease, levodopa-carbidopa intestinal gel (LCIG). The study showed that patients treated with LCIG for 12 weeks reported clinically meaningful and statistically significant improvements in "off" time compared to levodopa-carbidopa immediate release (IR) tablets, without increasing troublesome dyskinesia. 17 April 2012
Romania's Antiparkinson Association celebrates World Parkinson's Disease DayCelebrations included a conference on Parkinson's disease called "Do not leave them alone" in which people with Parkinson's could have interactive discussions with medical staff about the challenges they face in everyday life as well as find out about new technologies and treatments 11 April 2012
UCB marks World Parkinson's Disease Day with new 'Parkinson's Well-Being Map'Brussels, Belgium, 11th April 2012, 0700 CET UCB is announcing a new initiative for World Parkinson's Disease Day 2012 that is designed to support communication around all aspects of Parkinson's Disease (PD). The Parkinson's Well-Being Map is a visual tool designed to help people with PD discuss their health status and well-being with their care teams. A new video 'Living with Parkinson's Disease: Insights and Inspirations' is also shared today and gives a voice to people with Parkinson's on... 11 April 2012
BRAVE Awards 2012 to Recognize Caregivers Now Accepting NominationsThe BRAVE Awards, an international awards program intended to recognize everyday people who serve as caregivers, is now accepting nominations. Developed and implemented by Shire plc, the global specialty biopharmaceutical company, the program is designed to recognize the courage and dedication of non-professional caregivers. 02 April 2012

RSS feed - Subscribe to this page